The AIM-listed diagnostics manufacturer said the agreement made with ARKRAY Healthcare pvt Ltd (ARKRAY), a subsidiary of ARKRAY Inc. Japan, will focus on securing regulatory approvals for the HCV ID Kit in India.
Genedrive added that it would retain responsibility for product development, quality management and manufacturing, with commercial activities expected to begin in the latter part of its 2018/19 financial year.
ARKRAY will be responsible for sales, marketing, customer support and distribution activities across the region, the group said.
The development is another step in the firms push into global commercial territory, having begun commercial sales and shipments of its HCV ID Kit into the EMEA region in mid-March.
David Budd, Genedrive chief executive, said: "We are extremely pleased to extend our commercial reach into India with ARKRAY, who have established an extensive and respected diagnostic sales and support business in the Indian market. This agreement provides access to another important and very relevant region for Genedrive through a world class commercial partner."